- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05445908
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
October 17, 2023 updated by: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
A Phase 2 Clinical Study of SKB264 With/Without KL-A167 in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-negative Breast Cancer Who Have Not Received Prior Systemic Therapy
The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1(TNBC): exploratory phase of the efficacy and safety of the combination treatment.
Part 2(TNBC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .
Part 3(HR+/HER2- BC): The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
175
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: YiNa Diao
- Phone Number: 028-67252634
- Email: diaoyina@kelun.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410031
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- QuChang Ouyang
- Phone Number: 13973135318
- Email: oyqc1969@126.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Jiangsu Province Hospital
-
Contact:
- YongMei Yin, professor
- Phone Number: 13951842727
- Email: ym.yin@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males or females aged ≥ 18 and ≤ 75 years at the time of signing the informed consent form (ICF);
- Histological and/or cytological diagnosis of TNBC or HR+/HER2- BC based on pathology reports on recent biopsy samples or other pathological samples (central laboratory confirmation is not required);
- Patients have not received prior systemic chemotherapy for locally advanced, recurrent and metastatic disease;
- Ability to provide fresh or archival tumor tissue for biomarker testing and analysis;
- Patients with at least one measurable lesion per RECIST v1.1 criteria, and patients with only skin or bone lesions cannot be enrolled;
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with an expected survival of ≥ 12 weeks;
- Adequate organ and bone marrow function;
- Patients must recover from all toxicities due to prior treatment (recovery to ≤ Grade 1 based on CTCAE v5.0 assessment, or meeting the inclusion criteria in the protocol) with the exception of alopecia and vitiligo;
- Female subjects of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception during the study treatment period and for 6 months after the end of dosing (see Appendix for specific contraceptive measures);
- Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures.
Exclusion Criteria:
- History of other malignancies;
- Patients with a history of central nervous system (CNS) metastases or current CNS metastases.
- Imaging (CT or MRI) shows that the tumor has invaded large blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study;
- Received any systemic immune-stimulatory agents within 4 weeks prior to the first dose of study; Received any traditional Chinese medicine for approved anti-tumor indications within 2 weeks prior to the first dose of study;
- Received other clinical investigational drugs within 4 weeks or major surgery within 4 weeks prior to the first dose of the study treatment;
- Patients who required systemic corticosteroids (> 10 mg/day prednisone or equivalent; low-dose corticosteroids are allowed, such as ≤10 mg/day prednisone or equivalent, if the dose is stable for 4 weeks), or other immunosuppressive therapy within 2 weeks prior to the first dose. Steroids are allowed as prophylaxis for hypersensitivity reactions;
- Patients who occurred arteriovenous thrombosis within 6 months prior to the first dose of study treatment,Such as cerebrovascular accidents, deep vein thrombosis, and pulmonary embolism, etc.
- Prior treatment with a TROP2-targeted drug or checkpoint inhibitor ;
- Serious or uncontrolled cardiac disease or clinical symptoms requiring treatment;
- Patients with (noninfectious) interstitial lung disease (ILD) or history of pneumonia requiring steroid therapy; patients with serious pulmonary function impairment due to lung disease;
- Uncontrolled systemic disease as judged by the investigator, included uncontrolled hypertension, uncontrolled diabetes, pesence of pleural effusion, pericardial effusion, or ascites that is clinically symptomatic or requires repeated drainage;
- Active autoimmune disease requiring systemic treatment within the past 2 years;
- Active hepatitis B or hepatitis C; known history of positive human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); positive syphilis antibody test;
- Known hypersensitivity to the study drug or any of its components, or severe allergic reactions to other monoclonal antibodies;
- Pregnant or lactating women;
- Any patient whose condition deteriorates rapidly during the screening process prior to the first dose, such as severe changes in performance status, unstable pain requiring adjustment of analgesic therapy, etc;
- Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SKB264+KL-A167(Part1,TNBC)
Participants received SKB264 followed by KL-A167
|
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
|
Experimental: SKB264(Part2,TNBC)
Participants received SKB264
|
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
|
Experimental: SKB264+KL-A167(Part2,TNBC)
Participants received SKB264 followed by KL-A167
|
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
|
Experimental: SKB264(Part3,HR+/HER2- BC)
Participants received SKB264
|
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
|
Experimental: SKB264+KL-A167(Part3,HR+/HER2- BC)
Participants received SKB264 followed by KL-A167
|
SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events (AEs)
Time Frame: From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months
|
Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months
|
Objective Response Rate (ORR)
Time Frame: From baseline to first documented objective response, up to 24 months
|
Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1.
|
From baseline to first documented objective response, up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From baseline to the first documented disease progression or date of death (whichever occurs first), up to 24 months
|
Progression-free survival (PFS) was defined as the time from baseline to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause.
PD was defined as at least a 20% increase in the sum of diameters of target lesions.
|
From baseline to the first documented disease progression or date of death (whichever occurs first), up to 24 months
|
Duration of response (DOR)
Time Frame: From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 24 months
|
Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response [CR] or partial response [PR]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.
DoR was measured for responding subjects (PR or CR) only.
|
From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 24 months
|
Disease control rate (DCR)
Time Frame: From baseline to date of first documented objective response (CR, PR, and SD), up to 24 months
|
Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate.
As per RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions.
|
From baseline to date of first documented objective response (CR, PR, and SD), up to 24 months
|
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of SKB264-ADC, SKB264-TAB and free KL610023
Time Frame: Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
|
Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of SKB264-ADC, SKB264-TAB and free KL610023
Time Frame: Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
|
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of KL-A167
Time Frame: Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
|
Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of KL-A167
Time Frame: Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: pre-dose, post-dose (each cycle is 14 days), up to 24 months
|
|
Anti-drug Antibodies (ADA) for SKB264 and KL-A167
Time Frame: Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: within 1 h before infusion of SKB264 (each cycle is 14 days), up to 24 months
|
Cycles 1-3, 5, 7, 9, and 11, every 6 cycles starting from Cycle 17 Day 1: within 1 h before infusion of SKB264 (each cycle is 14 days), up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 17, 2022
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
June 30, 2022
First Submitted That Met QC Criteria
June 30, 2022
First Posted (Actual)
July 6, 2022
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 17, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SKB264-Ⅱ-07
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple-negative Breast Cancer and HR+/HER2- BC
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Laura M. Spring, MDMerck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...RecruitingTriple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)United States
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
Peking UniversityRecruitingHER2-positive Breast Cancer | Triple-negative Breast CancerChina
-
Merrimack PharmaceuticalsSanofiCompletedER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer PatientsUnited States
-
Filipa Lynce, MDMerck Sharp & Dohme LLC; Zentalis PharmaceuticalsNot yet recruitingBreast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast TripleUnited States
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
Clinical Trials on SKB264
-
Klus Pharma Inc.RecruitingBreast Cancer | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Small-Cell Lung CancerUnited States, China
-
Sichuan Kelun Pharmaceutical Research Institute...RecruitingNon-small Cell Lung CancerChina
-
Klus Pharma Inc.Recruiting
-
Sichuan Kelun Pharmaceutical Research Institute...RecruitingSelected Subjects With Advanced Solid TumorsChina
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Sichuan Kelun Pharmaceutical Research Institute...Not yet recruitingMetastatic Breast Cancer
-
Sichuan Kelun Pharmaceutical Research Institute...Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Recruiting
-
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active, not recruitingTriple Negative Breast CancerChina
-
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Not yet recruitingTriple Negative Breast CancerChina
-
Klus Pharma Inc.Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.RecruitingNon-small Cell Lung CancerChina